Table 1.
Baseline characteristics of study patients.
| Clinical characteristic | COPD |
|---|---|
| Number | 275 |
| Sex | 32/243 |
| (Female/male) | (11.6/88.4) |
| Age | 70.8 ± 9.0 |
| Smoking status | 60/152/63 |
| (never/ex/smoker) | (21.8/55.3/22.9) |
| Smoking index | 33.1 ± 31.6 |
| BMI | 23.2 ± 4.1 |
| COPD years | 6.6 ± 7.7 |
| mMRC scores | 40/67/82/72/14 |
| (1/2/3/4/5) | (14.6/24.4/29.8/26.2/5.1) |
| CAT score | 16.6 ± 8.8 |
| SGRQ score | 35.6 ± 19.3 |
| FEV1, % | 52.2 ± 22.6 |
| FEV1%FVC, % | 56.6 ± 14.5 |
| GOLD stage | 33/76/128/78 |
| (I/II/III/IV) | (12.0/27.6/46.6/13.8) |
| EOS | 0.3 ± 0.9 |
| PLR | 151.1 ± 62.8 |
| SII | 745.5 ± 438.1 |
| SIRI | 1.9 ± 1.3 |
| PLT/RDW | 15.6 ± 3.9 |
| PLT/MPV | 21.5 ± 6.2 |
Data were shown as mean ± SD. GOLD COPD grades are defined as: grade I: post-bronchodilator FEV1 > 80% of predicted; grade II: post-bronchodilator FEV1 50–80% of predicted; grade III: post-bronchodilator FEV1 30–50% of predicted; and grade IV: post-bronchodilator FEV1 <30% of predicted.
BMI, body mass index; smoking index, smoking packs per day; FEV1, forced expiratory volume in 1 s; FVC, first vital capacity; PLR, platelet–lymphocyte ratio; SII, platelet × neutrophil/lymphocyte; SIRI, monocyte × neutrophil/lymphocyte; PLT/RDW, platelet counts–red cell distribution width ratio; PLT/MPV, platelet counts–mean platelet volume ratio.